Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Phathom Pharmaceuticals announced an 88% year-over-year increase in Q2 2026 net revenues to $74.3 million driven by growth in VOQUEZNA prescriptions. The company reduced operating expenses by 33% compared to Q2 2025 and achieved operating profitability excluding stock-based compensation. Phathom plans to initiate a Phase 3 clinical trial evaluating…